ALX Oncology Holdings Inc.

NASDAQ:ALXO

1.34 (USD) • At close November 12, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 0002.4800000000000000.5270.6551.2131.2561.2951.032
Cost of Revenue 00.220.2140.2070.2090.5130.5180.41300.280.3760.2590.2620.1520.005000.4790.5961.1031.1421.1770.938
Gross Profit 0-0.22-0.2142.273-0.209-0.513-0.518-0.4130-0.28-0.376-0.259-0.262-0.152-0.005000.0480.0590.110.1140.1180.094
Gross Profit Ratio 0000.917000000000000.09100.0910.090.0910.0910.0910.091
Reseach & Development Expenses 26.47134.65331.71741.78445.76629.48224.76325.19729.38226.74817.07320.89418.21411.2139.84912.1425.3287.6633.8286.7352.213.6283.733
General & Administrative Expenses 6.0966.8726.0456.2397.5097.2957.447.0227.2997.0417.6747.5786.3625.0864.3595.6834.4813.1721.4731.1080.9380.6790.588
Selling & Marketing Expenses 0-0.22-0.214-0.2070000000000000000000
SG&A 6.0966.6525.8316.0327.5097.2957.447.0227.2997.0417.6747.5786.3625.0864.3595.6834.4813.1721.4731.1080.9380.6790.588
Other Expenses 0-0.008-0.014-0.029-0.0010.3240.095-0.233-0.009-0.007-0.0110.0160.0140.0280.0260.005-0.111-0.3050.007-0.001-0.0020-0.002
Operating Expenses 32.56741.30537.54847.81653.27536.77732.20332.21936.68133.78924.74728.47224.57616.29914.20817.8259.80910.8355.3017.8433.1484.3074.321
Operating Income -32.567-41.525-37.762-48.023-53.275-36.777-32.203-32.219-36.681-33.789-24.747-28.472-24.576-16.299-14.208-17.825-9.809-10.787-5.242-7.733-3.034-4.189-4.227
Operating Income Ratio 000-19.36400000000000-15,080,372.250-20.469-8.003-6.375-2.416-3.235-4.096
Total Other Income Expenses Net 1.862.1262.1812.5512.2850.3242.0191.574-0.0090.8690.2140.0160.0140.0280.026-0.616-0.111-0.3050.007-0.001-0.0020-0.002
Income Before Tax -30.707-39.399-35.581-45.472-50.99-34.159-30.184-30.645-35.32-32.92-24.533-28.459-24.566-16.274-14.185-18.592-10.146-11.311-5.45-7.755-3.036-4.189-4.229
Income Before Tax Ratio 000-18.33500000000000-15,729,272.420-21.463-8.321-6.393-2.417-3.235-4.098
Income Tax Expense 000.1711.145-0.2090.696-1.6320.064-1.37-0.869-0.214-0.0210.0180.0310.0290.1820.0350.020.0040.0090.0080.0080.009
Net Income -30.707-39.399-35.581-45.472-50.99-34.159-28.552-30.709-35.32-32.051-24.319-28.438-24.566-16.274-14.185-18.774-10.181-11.331-5.454-7.764-3.044-4.197-4.238
Net Income Ratio 000-18.33500000000000-15,883,248.7310-21.501-8.327-6.401-2.424-3.241-4.107
EPS -0.58-0.76-0.71-0.93-1.24-0.84-0.7-0.75-0.87-0.79-0.6-0.7-0.61-0.4-0.35-0.5-0.34-0.33-0.16-0.35-0.14-0.19-0.19
EPS Diluted -0.58-0.76-0.71-0.93-1.24-0.84-0.7-0.75-0.87-0.79-0.6-0.7-0.61-0.4-0.35-0.5-0.34-0.33-0.16-0.35-0.14-0.19-0.19
EBITDA -32.567-41.305-37.548-47.816-53.275-33.58-29.584-32.219-36.586-33.705-24.689-28.456-24.556-16.265-14.177-17.82-9.915-11.013-5.122-7.622-2.925-4.08-4.132
EBITDA Ratio 000-19.28100000000000-15,076,142.1320-20.898-7.82-6.284-2.329-3.151-4.004